Health

FDA Approves Ekterly (sebetralstat) the First and Only Oral On-demand Treatment for Hereditary Angioedema (HAE)

DailyTrendDailyTrend
Jul 8, 2025 - 17:00
 0  0
FDA Approves Ekterly (sebetralstat) the First and Only Oral On-demand Treatment for Hereditary Angioedema (HAE)
CAMBRIDGE, Mass. & SALISBURY, England, July 7, 2025 (BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (Nasdaq: KALV) today announced that the U.S. Food and Drug Administration (FDA) has approved Ekterly (sebetralstat), a novel plasma kallikrein...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

FDA Approves Vizz (aceclidine ophthalmic solution) for the Treatment of Presbyopia

FDA Approves Vizz (aceclidine ophthalmic solution) for ...

DailyTrend Aug 4, 2025  0  0

Susan Monarez Faces Daunting Challenges as C.D.C. Director

Susan Monarez Faces Daunting Challenges as C.D.C. Director

DailyTrend Aug 1, 2025  0  0

A Cancer Patient Chose Assisted Death. That Wasn’t the Last Hard Choice.

A Cancer Patient Chose Assisted Death. That Wasn’t the ...

DailyTrend Aug 3, 2025  0  0

What’s a Potato? A Nine-Million-Year-Old Tomato

What’s a Potato? A Nine-Million-Year-Old Tomato

DailyTrend Jul 31, 2025  0  0

FDA Approves Vostally (ramipril) Oral Solution for the Treatment of Hypertension in Adults

FDA Approves Vostally (ramipril) Oral Solution for the ...

DailyTrend Aug 4, 2025  0  0

FDA Approves Alhemo as Once-Daily Prophylactic Treatment to Prevent or Reduce the Frequency of Bleeding Episodes for Adults and Children 12 Years of Age and Older with Hemophilia A or B (HA/HB) Without Inhibitors

FDA Approves Alhemo as Once-Daily Prophylactic Treatmen...

DailyTrend Aug 3, 2025  0  0